See more : IDEX Biometrics ASA (IDEX.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Eris Lifesciences Limited (ERIS.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eris Lifesciences Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hapbee Technologies, Inc. (HAPBF) Income Statement Analysis – Financial Results
- Nordea Bank Abp (NDA-SE.ST) Income Statement Analysis – Financial Results
- YASH TRADING & FINANCE LTD. (YASTF.BO) Income Statement Analysis – Financial Results
- JAC Recruitment Co., Ltd. (2124.T) Income Statement Analysis – Financial Results
- PT Singaraja Putra Tbk (SINI.JK) Income Statement Analysis – Financial Results
Eris Lifesciences Limited (ERIS.NS)
About Eris Lifesciences Limited
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.91B | 16.62B | 13.26B | 11.93B | 10.58B | 9.67B | 8.56B | 7.25B | 5.97B | 5.46B | 5.09B | 3.93B |
| Cost of Revenue | 9.66B | 3.52B | 2.61B | 2.42B | 1.79B | 1.55B | 1.36B | 1.07B | 1.01B | 961.74M | 1.00B | 750.33M |
| Gross Profit | 10.25B | 13.09B | 10.65B | 9.51B | 8.79B | 8.12B | 7.19B | 6.18B | 4.96B | 4.49B | 4.08B | 3.18B |
| Gross Profit Ratio | 51.47% | 78.80% | 80.33% | 79.72% | 83.11% | 83.96% | 84.08% | 85.27% | 83.15% | 82.37% | 80.28% | 80.91% |
| Research & Development | 57.18M | 61.00M | 327.38M | 50.92M | 41.96M | 41.12M | 7.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 714.79M | 471.75M | 504.09M | 430.35M | 352.91M | 317.71M | 335.05M | 362.83M | 332.10M | 362.33M | 318.47M | 309.23M |
| Selling & Marketing | 1.79B | 1.39B | 1.02B | 1.08B | 1.46B | 1.19B | 924.96M | 696.35M | 709.94M | 604.41M | 1.02B | 547.43M |
| SG&A | 4.79B | 1.86B | 1.52B | 1.51B | 1.82B | 1.50B | 1.26B | 1.06B | 1.04B | 966.74M | 1.34B | 856.66M |
| Other Expenses | 238.15M | 111.53M | 10.36M | 4.55M | 36.62M | 17.40M | 7.42M | 860.00K | 170.00K | 780.00K | 1.80B | 40.00K |
| Operating Expenses | 4.94B | 8.90B | 6.40B | 5.62B | 5.56B | 5.01B | 4.23B | 3.73B | 3.42B | 3.43B | 3.14B | 2.31B |
| Cost & Expenses | 14.91B | 12.42B | 9.01B | 8.04B | 7.35B | 6.56B | 5.59B | 4.79B | 4.43B | 4.40B | 4.15B | 3.06B |
| Interest Income | 70.10M | 22.99M | 60.98M | 22.85M | 16.06M | 10.96M | 9.96M | 7.68M | 4.18M | 840.00K | 1.70M | 2.76M |
| Interest Expense | 848.01M | 261.68M | 41.46M | 18.02M | 21.62M | 228.95M | 105.50M | 2.42M | 1.20M | 180.00K | 2.46M | 7.12M |
| Depreciation & Amortization | 1.83B | 1.17B | 647.05M | 429.85M | 502.58M | 363.54M | 256.42M | 227.61M | 203.56M | 155.14M | 47.68M | 34.85M |
| EBITDA | 6.99B | 5.48B | 5.11B | 4.39B | 3.84B | 3.77B | 3.48B | 2.93B | 1.68B | 1.25B | 1.03B | 873.36M |
| EBITDA Ratio | 35.08% | 32.97% | 37.46% | 36.42% | 35.81% | 36.19% | 37.91% | 37.26% | 28.82% | 22.30% | 19.50% | 23.20% |
| Operating Income | 5.18B | 4.22B | 4.25B | 3.88B | 3.22B | 3.09B | 2.96B | 2.46B | 1.54B | 1.06B | 942.73M | 866.15M |
| Operating Income Ratio | 26.02% | 25.37% | 32.01% | 32.50% | 30.42% | 31.94% | 34.65% | 33.87% | 25.82% | 19.42% | 18.53% | 22.04% |
| Total Other Income/Expenses | -869.33M | -248.41M | -3.25B | -16.73M | 78.60M | 64.06M | 157.47M | 238.24M | 2.98M | 34.42M | 40.52M | -34.76M |
| Income Before Tax | 4.31B | 4.05B | 4.42B | 3.94B | 3.31B | 3.17B | 3.12B | 2.64B | 1.54B | 1.09B | 983.25M | 831.39M |
| Income Before Tax Ratio | 21.66% | 24.35% | 33.34% | 33.08% | 31.31% | 32.81% | 36.49% | 36.38% | 25.87% | 20.06% | 19.32% | 21.15% |
| Income Tax Expense | 341.85M | 304.83M | 364.09M | 393.62M | 348.43M | 262.11M | 172.51M | 218.72M | 195.87M | 201.56M | 277.88M | 246.99M |
| Net Income | 3.92B | 3.82B | 4.06B | 3.55B | 2.96B | 2.91B | 2.94B | 2.42B | 1.34B | 892.34M | 704.19M | 581.98M |
| Net Income Ratio | 19.68% | 23.00% | 30.62% | 29.78% | 28.02% | 30.07% | 34.37% | 33.39% | 22.37% | 16.36% | 13.84% | 14.81% |
| EPS | 28.82 | 28.10 | 29.89 | 26.16 | 21.61 | 21.15 | 21.39 | 17.95 | 9.71 | 6.49 | 5.12 | 4.23 |
| EPS Diluted | 28.79 | 28.07 | 29.88 | 26.14 | 21.59 | 21.13 | 21.39 | 17.95 | 9.71 | 6.49 | 5.12 | 4.23 |
| Weighted Avg Shares Out | 136.01M | 135.98M | 135.87M | 135.78M | 137.19M | 137.52M | 137.50M | 137.50M | 137.50M | 137.50M | 137.50M | 137.50M |
| Weighted Avg Shares Out (Dil) | 136.17M | 136.17M | 135.91M | 135.88M | 137.30M | 137.64M | 137.50M | 137.50M | 137.50M | 137.50M | 137.50M | 137.50M |
Source: https://incomestatements.info
Category: Stock Reports